Persistent Opioid Use After Ophthalmic Surgery in Opioid-Naïve Patients and Associated Risk Factors

Written by: Priya Sharma Vakharia, MDRetina Vitreous Associates of FloridaPalm Harbor & St. Petersburg, FL January 2022 Ung C, Yonekawa Y, Waljee J, et al. Persistent opioid use after ophthalmic surgery in opioid-naïve patients and associated factors. Ophthalmology 2021; 128(9): 1266-1273. This is a retrospective claims-based cohort analysis, using a database (Optum ClinformaticsÒ DataMart Database) […]

Risk Factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents

Written by: Wenlan (Wendy) Zhang, MD October 2021 Lauermann P, Klingelhöfer A, Mielke D, van Oterendorp C, Hoerauf H, Striebe NA, Storch MW, Pfeiffer S, Koscielny J, Sucker C, Bemme S, Feltgen N. Risk Factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents. Ophthalmol Retina. 2021 Aug;5(8):e23-e29. Many […]

Development of Macular Atrophy after Pars Plana Vitrectomy for Myopic Traction Maculopathy and Macular Hole Retinal Detachment in Pathologic Myopia

Written by: Musa Abdelaziz, MD October 2021 Fang, Y et al. “Development of macular atrophy after pars plana vitrectomy for myopic traction maculopathy and macular hole retinal detachment in pathologic myopia.” Retina. 2020 Oct;40(10):1881-1893. DOI: 10.1097/IAE.0000000000002709. Pathologic myopia (PM) is a major cause of legal blindness worldwide. The most serious lesion associated with severe vision […]

End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Written by: Philip P. Storey, MD October 2021 Khanani A, Callanan D, Dreyer R, Chen S, Howard J, Hopkins J, Lin C, Lorenz-Candlin M, Makadia S, Patel S, Tam T, Gune S. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina 2021;5:775-787. […]

Epiretinal Membrane Surgery after Retinal Detachment Repair: Visual Acuity Outcomes and OCT Analysis

Written by: Daniel Su, MD October 2021 Soares RR, Mahmoudzadeh R, Salabati M, Massenzio E, Israilevich R, Patel SN, Hinkle J, Kuriyan AE, Hsu J, Garg SJ, Khan MA. Epiretinal Membrane Surgery after Retinal Detachment Repair: Visual Acuity Outcomes and OCT Analysis. Ophthalmol Retina. 2021 Mar 29:S2468-6530(21)00103-2. Epiretinal membrane (ERM) formation commonly occurs after primary […]

Microcystic Macular Edema and Cystoid Macular Edema Before and After Epiretinal Membrane Surgery

Written by: Edward H. Wood, MD September 2021 Lee Dong Hyun, Sung Eun Park, and Christopher Seungkyu Lee. 2020. “Microcystic Macular Edema and Cystoid Macular Edema Before and After Epiretinal Membrane Surgery.” Retina Publish Ahead of Print (December). https://doi.org/10.1097/IAE.0000000000003087. This study is clinically useful by expanding our understanding of imaging biomarkers of idiopathic epiretinal membranes (ERM) […]

Machine Learning Can Predict Anti–VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema

Written by: Mohsin H. Ali, MD September 2021 Gallardo, Mathias, et al. “Machine Learning Can Predict Anti–VEGF Treatment Demand in a Treat-and-Extend Regimen for Patients with Neovascular AMD, DME, and RVO Associated Macular Edema.” Ophthalmology Retina, vol. 5, no. 7, 2021, pp. 604–624., doi:10.1016/j.oret.2021.05.002.  Machine learning artificial intelligence models have the potential to improve our […]

Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration

Written by: Akshay S. Thomas, MD August 2021 Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2021;128(7):1027-1038.   Treatment options for wet AMD in 2019 included off-label use of bevacizumab or use of an FDA-approved agent, ranibizumab or […]